This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

EDAP Granted Special Temporary Reimbursement For Ablatherm-HIFU In France

LYON, France, Feb. 2, 2011 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today it has been granted a special temporary reimbursement for Ablatherm-HIFU for the treatment of localized prostate cancer by the French National Authority for Health ("HAS"). The grant follows a comprehensive review of Ablatherm-HIFU clinical results. This step by HAS reflects a new reimbursement process dedicated to innovative therapies, which allows Ablatherm-HIFU technology to be granted temporary reimbursement while setting up a dedicated treatment registry for the next five years.

Marc Oczachowski, Chief Executive Officer of EDAP TMS, commented, "This temporary reimbursement is a major milestone towards establishing definitive reimbursement in France for our HIFU treatment for localized prostate cancer. It clearly validates Ablatherm-HIFU's growth potential in France. HAS estimates the potential number of patients to be treated annually by our technology to be approximately 10,000 primary care patients and 800 radiotherapy failure patients. We see this potential as a significant expansion opportunity compared to a total of 800 patients treated last year in France without reimbursement."

Pierre Reboul, Sales Director for EDAP TMS in France, commented, "We are very pleased with this positive recommendation from HAS, which is a definitive first step in the reimbursement process. It is a significant recognition of our HIFU treatment option by the French Authorities. It will allow HIFU centers in France to receive reimbursement for Ablatherm treatments and to contribute treatment results to a dedicated registry database. We will continue to work closely with the authorities in the coming months to establish the temporary reimbursement rate. We will pursue our close cooperation with the French Urology Association to facilitate implementation of such reimbursement structure across selected clinical sites."

Patient population covered by such reimbursement includes selected primary care patients with localized prostate cancer who cannot undergo surgery or radiotherapy and patients with recurrence of their cancer after radiotherapy.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,879.55 -256.17 -1.41%
S&P 500 2,077.01 -24.03 -1.14%
NASDAQ 4,940.0350 -42.7740 -0.86%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs